introduction
The comprehensive geriatric assessment (CGA) is a multidisciplinary evaluation of an older individual's functional, psychological and nutritional statuses, cognition, social support, and comorbidity. This assessment can detect geriatric problems and potentially improves survival, physical, and cognitive state of patients as well as increases an elderly person's chances of staying at home longer [1] [2] [3] [4] . With regard to elderly cancer patients, CGA components have been shown to be prognostic factors of survival (such as functional status and quality of life) and even associated with changes in cancer treatment (such as functional status and malnutrition) [5] [6] [7] . Although randomized controlled trials evaluating the impact of CGA-based interventions in older cancer patients to provide definite evidence on its efficacy to improve survival are still rare, existing literature provides growing evidence that CGA can predict morbidity and mortality in older cancer patients [8] .
Since 2005, the application of the CGA for cancer patients >70 has been recommended by the International Society of Geriatric Oncology [9] . However, its systematic application to this population does not seem essential as many patients can be treated according to the standard treatment protocol without major modification [10] [11] [12] . Similar findings have been derived from the general population as improved outcomes are observed in unfit patients, suggesting that healthy older people should be excluded of the process [4] .
The current challenge at hand is to identify individuals for whom the CGA would be the most beneficial, justifying the need for a validated screening instrument. Several screening methods to identify frail patients are available [13] [14] [15] [16] [17] . They usually have to be administered by clinical personnel [13] [14] [15] 17] . In addition, most have been validated in the clinical geriatric context but not with cancer patients and thus do not necessarily take into account the side-effects of cancer treatment. The Vulnerable Elders Survey (VES-13), a selfadministered questionnaire, is one such tool that has been developed based on a large population of 6000 patients aged over 65 years [18] . It has since been evaluated in cancer patients by several studies but sample sizes are limited with heterogeneous cancer populations. Importantly, this tool has been evaluated against various reference exams [19] [20] [21] [22] [23] leading to different estimates of its screening performances, as highlighted in an recent editorial [24] .
Current work on geriatric screening tools raises two issues. First, the development of a screening tool is necessary to individualize older cancer patients who would benefit from a CGA. This approach offers advantages both for the rationalization of the use of medical resources for the health care system and also to spare the patient from unnecessary clinical and biological examinations. In addition, from a methodological point of view, the reference exam to which the screening tool will be compared needs to be defined with rigor [25] . We propose to address these two issues.
Using data collected previously in a multicenter study focusing on a cohort of elderly cancer patients, we carried out a series of analyses to finalize the choice of a high-performing screening tool. Specifically, for the development of this screening test, we wish to ensure that none of the 'at risk' patients will be missed, thus prioritizing sensitivity over specificity. methods patients Our research was elaborated based on a regional multicenter prospective study funded by a 2003 French clinical research program (NCT00210249 [26] ). The primary objective of this study was to assess the role of the CGA in the management of elderly patients treated for a cancer with chemotherapy. Patients aged >70 years (no upper age limit) scheduled to receive first-line chemotherapy for various types of cancer [colon, pancreas, stomach, ovary, bladder, prostate, lung cancer, non-Hodgkin's lymphoma (NHL), or cancer of unknown primary origin] were eligible for inclusion. Breast cancer patients were not included as very few elderly patients receive first-line chemotherapy. Patients with known central nervous system metastases were excluded. The protocol was approved by institutional review boards and ethics committees and was conducted in accordance with the Declaration of Helsinki, Good Clinical Practices, and local ethical and legal requirements. All patients provided written informed consent for their participation.
baseline assessment
The geriatric evaluation consultation was carried out after an initial specialized oncology consultation. This evaluation assessed the patient's comorbidities, cognitive functions, mood disorders, nutritional and functional status, disabilities as well as the main geriatric syndromes, and the current medication of the elderly patient. The patient was seen by the clinical research nurse for the following questionnaires and scales: Instrumental (IADL) and Activities in Daily Living (ADL) questionnaires, the Geriatric Depression Scale (GDS-15), and a quality of life selfquestionnaire (QLQ-C30). The geriatrician was responsible for completing the Cumulative Illness Rating Scale for Geriatrics (CIRS-G), the MiniMental Status Exam (MMSE), and the Mini Nutritional Assessment (MNA) as well as for performing the 'Timed Get Up and Go' (GUG) evaluation. As necessary, the oncologist scheduled interventions with various health care practitioners (social worker, nutritionist, physiotherapist, team of psychologists, and/or psychiatrist) as well as any necessary supplementary examinations such as extra blood analyses. Geriatric assessment data were blinded to the physician. These questionnaires and scales have been validated including cut-off values for defining abnormal test results. The domain covered by each of these questionnaires, the range of their respective scores, as well as cut-off values for defining abnormal scores are summarized in Table 1 .
reference exam
In order to evaluate a screening tool, a clear definition of the reference exam must first be provided. No recognized definition for such reference tool is available in the literature [24] . We retained a set of seven validated questionnaires (ADL, IADL, MMSE, GDS-15, MNA, CIRS-G, and GUG), which are routinely used and often considered as components of the CGA [8] . Similarly, a clear definition of what constitutes an abnormal reference should be provided. We considered the presence of at least one questionnaire with an impaired score as an abnormal reference exam. As exploratory analyses, we also investigated five additional reference exams. We considered using at least two abnormal scores based on the aforementioned set of seven questionnaires. Next, we considered leaving out either the ADL or the IADL and using at least one or two questionnaires with an impaired score.
proposition of a screening tool
We chose to assess the G-8 screening tool consisting of eight items: a selection of seven items from the MNA questionnaire as well as an indication of age. As such, the G-8 tool shares common questions with the MNA short form, although the latter was not specifically developed for cancer patients [37] . Items selected from the MNA questionnaire included questions relating to nutritional status [food intake (MNA item A), weight loss (item B), body mass index (item F)], motor skills (item C), psychological status (item E), number of medications (item H), and selfperception of health (item P). Age was considered in three categories (<80, 80-85, and >85) as it is typically included in frailty criteria [14, 18] . We maintained the same scores as those used in the original MNA questionnaire and used a score of 0 (>85) to 2 (<80) for age. Overall, the G-8 score ranged from 0 (heavily impaired) to 17 (not at all impaired). The G-8 questionnaire is provided in Table A1 .
The choice of the items that constituted the G-8 was driven by earlier findings. Following a preliminary analysis [26] , we investigated factors . Advanced disease stage, male gender, low MNA score, and impaired GUG were significantly and independently associated with early death risk. These preliminary results highlighted the value of the MNA score when evaluating elderly cancer patients as compared with other test scores specific to other domains. These results appear coherent as the content of this questionnaire includes items not only related to the nutritional status of the patient but also items oriented toward the exploration of cognitive or mood troubles as well as disabilities or comorbidities that are present in geriatric questionnaires of the CGA. We thus expected items of the G-8 to be strongly correlated with scores of geriatric questionnaires. Although in brief, items of the G-8 tend to cover domains usually addressed by the CGA. As such, we anticipated strong associations.
statistical analyses
Qualitative variables were described using counts and proportions. Quantitative continuous variables were described using means and standard deviations for normal data or medians and ranges otherwise.
Associations between qualitative variables were tested using the chi-square test or the Fisher's exact test depending on the sample sizes. Performance of the G-8 tool was evaluated using sensitivity (Se), specificity (Sp), receiver operating curve (ROC), and area under the ROC curve (AUC). Confidence intervals (95% CI) are reported. (Table 2) . Median age was 77 years (70-99 years) with slightly more males (59%). The main cancer types and locations were lymphomas (30%), cancer of the colon (28%), stomach (10%), lung (10%), pancreas (6%), prostate (6%), bladder (5%), and ovary (4%).
Most of the solid tumors were of advanced stage (53%). Almost half of the NHL patients were of International Prognostic Index (IPI) stage 2-3 (46%). Across all tumor types, The seven evaluations were available for 339 patients (93%). Complete assessment was significantly more often available for subjects with localized disease (97% for localized versus 90% for advanced disease), men (95% for men versus 90% for women), and for patients with better performance status [98% for Eastern Cooperative Oncology Group (ECOG) 0-1 versus 85% for ECOG [2] [3] [4] . Patients who completed the assessment were also significantly younger (mean age 77·5 versus 82·2). The questionnaire with the lowest completion rate was the MMSE (92%) while the CIRS-G was available for all patients. Among the patients who completed all seven evaluations, the ADL questionnaire had the highest number of 'normal' nonimpaired scores (83%) compared with 28%, 36%, and 55% for the IADL, MNA, and GDS-15, respectively. These distributions of scores were similar when we considered the global population (Table 1) .
reference exams and rules
When the seven questionnaires were considered, 94% of the population presented with at least one impaired score and 76% presented with two or more impaired scores. Proportions of subjects with an abnormal reference exam are presented in Table 3 using other rules.
performance of the screening tool
As expected, items of the G-8 screening tool showed strong associations with at least one of the geriatric evaluations (Table 4 ). Approximately 82% of the population presented an impaired G-8 score. When considering an impaired reference standard as at least one impaired score, the sensitivity and specificity estimates were close, whether the reference standard included all seven questionnaires, excluded the ADL, or excluded the IADL. Similar results apply when considering an impaired reference standard as two impaired scores, although the specificity fell drastically (down to 45%) for relatively smaller gains in sensitivity. The resulting ROC curves for the G-8 against the various reference exams were very similar, leading to comparable AUC estimates. We show the ROC curve representing the G-8 screening tool against the reference exam consisting of the seven questionnaires (Figure 1) .
When retaining the seven questionnaires as part of the reference exam, the ROC curves suggested that cut-off values ∼14 would provide good sensitivity estimates, of at least 80%, without deteriorating the specificity excessively (not <60%).
discussion
Based on a multicenter cohort study, we carried out the first evaluation of the G-8 screening tool for geriatric oncology. We also discussed the definition of the reference exam it should be compared with. The G-8 tool incorporating elements of the MNA questionnaire and age is thus proposed with the selected items covering multiple domains usually assessed by the geriatrician when performing the CGA: disability, nutrition, cognition, depression, and comorbidities. As in the MNA questionnaire, items specific on mood or cognition disorders, dependence, and comorbidities are highly subjective, and as such cannot be considered as a valuable evaluation of these domains, but rather global and/or subjective assessments. Moreover, it should be acknowledged that the G-8 tool is not aimed at replacing the expertise of geriatricians for the diagnosis of frailty. Rather, it should be used as a screening tool to identify patients in need for a further assessment and appropriate care.
Selection of the optimal cut-off value of the screening tool should rely on the desired properties of the tool under development. Because of the duality between sensitivity and specificity, both parameters cannot be simultaneously maximized. When developing a screening test, we wish to ensure that none of the at risk patients will be missed. Thus the sensitivity should be prioritized over the specificity. Our analysis suggested that a threshold value at 14 (≤14 versus >14) would provide good sensitivity estimates for the G-8 of at least 80%, without deteriorating the specificity under 60%.
As recently acknowledged by Molina-Garrido et al. [24] , currently, there is no one standard model of CGA accepted in the scientific community. A standard model composed of validated scales that would enable standardization of studies and results is needed. Our selection of seven tests and questionnaires that have been individually validated in geriatric oncology is thus coherent and sensible.
Depending on our definition of being at risk, the prevalence varied between 60% and 94%. Although these estimates could appear high, it should be noted that our target population included first-line chemotherapy elderly patients and as such a large proportion of advanced disease (about two-thirds in our sample). We expect that a general population of elderly cancer patients will involve a smaller proportion of advanced disease leading to lower estimates of at risk subjects.
We defined being at risk as having at least one or two areas of impairments when assessing the multiple dimensions of the physical and psychological conditions of the older cancer patient. We preferred the threshold of one abnormal questionnaire since our objective is to be sensitive in the detection of oncological frailty. Still, this choice may be debatable since patients with only one abnormal questionnaire do not necessarily need the intervention of a geriatrician in all cases.
The simultaneous inclusion of the ADL and IADL can also be discussed. Indeed, one could at first argue that both focus on the patient's autonomy and as such could be redundant. However, the two scales do not address the same stage of independence with IADL referring to skills required to maintain usual activities in the community (ability to shop, managing money, etc.), which are affected earlier than the skills encompassed by the ADL that are required to maintain very basic home activities (ability to bath, dress, etc.). It is therefore expected that skills impaired on ADL will be observed in the later stage of disability and should be identified relatively easily. On the other hand, impaired IADL skills are probably more subtle to identify during a standard consultation. Identifying and observing abnormal IADL can be considered as an early stage of disability. Furthermore, four questions of the IADL questionnaire have been shown to be highly correlated with cognitive deficiencies [38] . Given the high prevalence of cognitive impairment in the elderly [39] , impairment on the IADL scale should thus be accounted for. Finally, concerning the IADL, Lawton [28] originally suggested that certain activities such as shopping, preparing meals, and housework were gender-based and thus less representative for males so should only be evaluated for female patients. While this issue was also recently debated in the context of geriatric screening tools [40] , this distinction did not appear relevant in our dataset. Indeed, we applied both approaches when performing our analysis but did not notice any gender-based differences in terms of prevalence of subjects with an abnormal IADL score (data not shown). As of today, there is no clear definition of what should constitute the reference exam when evaluating a screening tool aimed at detecting old cancer patients in need for a CGA. The existing literature focusing on the validation of the VES-13 questionnaire is an illustration of this issue since it has been compared with very various reference exams [19] [20] [21] [22] . Impairment on the CGA was defined either as meeting the cutoff scores for impairment on two of seven individual tests within the CGA [19] (including ADL, IADL, Charlson index, and other usual tests) or as at least two abnormal scores of another set of seven questionnaires [21] or as having impairment in two or more domains (ADL and IADL), or being cognitively impaired (MMS ≤24) [20] . With regard to the only large study available, the reference exam is not systematically clearly defined [22] . The experience of the evaluation of the VES-13 highlights the importance of properly defining the reference exam.
This first evaluation has some limits. One could argue that the social environment and biological variables were not considered in the screening tool. While potentially informative, some sociocultural variables were collected through a questionnaire developed for the purpose of the ongoing study. It was not validated previously, and we thus considered that it should not be considered part of the reference exam. Although some biological variables can be associated with chemotherapy-related toxicity, their evaluation is often part of the routine oncological assessment and as such cannot be considered as a component of the CGA. Finally, the QLQ-C30 questionnaire provided valuable information but unlike other questionnaires, it is not a usual component of the geriatric evaluation. Given the design of the study, reproducibility of the G-8 could not be evaluated and should be addressed in a future study. Similarly, it would be of particular interest to confirm these preliminary findings in a larger population allowing us to address a broader range of treatments (chemotherapy, surgery, and radiotherapy) or cancer types (e.g. by including breast cancers) through subgroup analyses. Finally, the VES-13 was not initially included in our study and as such could not be assessed.
Although the lack of a common reference tool makes the comparison of screening tools particularly complex, these preliminary results are promising. When compared with a reference exam defined as the set of seven geriatric evaluations (ADL, IADL, MNA, MMSE, GDS-15, CIRS-G, and GUG), this first evaluation suggests good screening classification properties for the G-8 tool for use in geriatric oncology. We believe its excellent sensitivity and reasonable specificity as well as the ease of administration make the G-8 a promising screening tool, which now requires validation in a larger-scale prospective study. original articles Annals of Oncology
